Resumen de: EP4186563A1

The present disclosure provides a corona virus killing agent. In particular, the present disclosure provides a corona virus killing agent containing chlorous acid water. In particular, the present disclosure provides a method for killing corona virus, using chlorous acid water. The free chlorine concentration of the chlorous acid water (as Cl = 35.45) may be at least 5 ppm or greater in the absence of organic matter. The content of chlorous acid in the chlorous acid water (as HClO2 = 68.46) may be at least 200 ppm or greater in the presence of organic matter such as when disinfecting hands/fingers. The corona virus may be SARS corona virus (SARS-CoV), MERS corona virus (MERS-CoV), or the 2019 novel corona virus (SARS-CoV-2).

Resumen de: WO2022020569A1

The present invention provides methods, assays and kits for assessment of patients positive for SARS-CoV-2 infection and methods of diagnosis and treatment of COVID-19 disease and for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine- associated disease and adverse events, and for evaluation, treatment and management of patients who develop vaccine-associated disease. The invention provides methods and assays for identification and characterization of inborn errors of type I interferon immunity and also auto-antibodies against Type I IFNs that are associated with severe COVID-19 disease or that are correlated and linked with vaccine- associated disease. The invention further provides methods of diagnosing and determining altered response to or susceptibility to SARS-CoV-2 infection or to live attenuated virus vaccines and for applicable and suitable treatment of COVID-19 disease or vaccine-associated disease.

Resumen de: WO2022045935A1

The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to a nucleic acid that encodes RBD-S of SARS-CoV-2, to an expression cassette and a vector based thereon, as well as to a recombinant AAV5 (adeno-associated virus serotype 5)-based virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.

Resumen de: AU2020340881A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property (1) Organization11111111111111111111111I1111111111111ii111liiili International Bureau (10) International Publication Number (43) International Publication Date W O 2021/045836 Al 11 March 2021 (11.03.2021) W IPO I PCT (51) InternationalPatent Classification: York 10591 (US). BAUM, Alina; c/o Regeneron Phar A61K39/215(2006.01) A61K45/06 (2006.01) maceuticals, Inc., 777 Old Saw Mill River Road, Tarry A61K39/395 (2006.01) C07K16/10 (2006.01) town, New York 10591 (US). CHEN, Gang; c/o Regen (21) International Application Number: eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, PCT/US2020/039707 Tarrytown, New York 10591 (US). GERSON, Cindy; c/ o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Riv (22) International Filing Date: er Road, Tarrytown, New York 10591 (US). HANSEN, 25 June 2020 (25.06.2020) Johanna; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (25)FilingLanguage: English HUANG, Tammy; c/o Regeneron Pharmaceuticals, Inc., (26) Publication Language: English 777 Old Saw Mill RiverRoad, Tarrytown, New York 10591 (30)PriorityData: (US). KYRATSOUS, Christos; c/o Regeneron Pharma 300) ,312 P r Data: 2020(02.0ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, 63/004,312 02April2020(02.04.2020) US New York 10591 (US). LEE,Wen-Yi; c/o RegeneronPhar 63/014,687 23 April 2020 (23.04.2020) US maceutic

Resumen de: WO2023092069A1

The disclosure provides coronavirus mRNA vaccines, including booster vaccines, directed against one or more spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.

Resumen de: US2023160804A1

The disclosure relates to hematological parameters of viral infection. More specifically, the present disclosure relates to automated volume biomarkers lymph index and monocyte distribution width (MDW) for early detection of Coronavirus infection. The invention also relates to a method, device and computer executable program for early diagnosis of SARS-CoV-2 infection using volume biomarker lymph index and monocyte distribution width (MDW). According to some technical solutions of the present invention, the automated volumetric parameter lymph index and MDW can be used as viral biomarkers to help healthcare workers in the out-patient department or fever clinic to rapidly identify those who might be infected with SARS-CoV-2 and to provide valuable information for triage decision making.

Resumen de: WO2023091111A1

The present invention relates to the ACE-2 enzyme inhibitory effects of essential oils obtained from the aerial parts of Eucalyptus globulus and Eucalyptus citriodora plants and the treatment of Covid-19.

Resumen de: WO2023089243A1

The present invention is directed to SH3 domain derivatives having a specific binding affinity to receptor binding domain (RBD) of SARS-CoV-2 spike protein. In this respect, the invention specifically provides SH3 domain derivatives of nephrocystin (NPHP1) binding to RBD of SARS-CoV-2 spike protein. The present invention is also directed to the prevention and treatment of COVID-19.

Resumen de: WO2023089196A1

The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2 and that have been selected for potent cross-reaction and cross-neutralization between the original Wuhan strain and the Alpha, Beta, Gamma, Delta, and Mu variants of concern.

Resumen de: AU2021368757A1

A method of treating acute respiratory failure (ARF) and/or acute respiratory distress syndrome (ARDS) (optionally caused in a subject afflicted with COVID-19) in a subject in need thereof, which includes administering to the subject a therapeutically effective amount of a composition or combination including a tetrahydrocannabinol (THC), derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof and, optionally, one or more of an interferon (IFN), derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof, a fluvoxamine, derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof, an acetylcysteine, derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof.

Resumen de: WO2023091920A1

Here, the inventors report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally, RBD-binding antibodies could be categorized into 3 distinct classes based on their binding profiles against RBD mutant constructs. The inventors identified VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, this study identifies that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.

Resumen de: WO2023091727A1

The present disclosure provides kits and methods for detecting and/or quantifying coronavirus from aerosols and droplets.

Resumen de: WO2023092028A1

Disclosed are methods of preventing or treating a coronavirus infection in a blood cancer patient having received a cellular therapy by administration of a synthetic MVA-based vaccine.

Resumen de: WO2023091719A1

Devices, systems, and methods are provided device analyzing excreta of a subject using a toilet that include a housing mountable on a toilet adjacent the toilet bowl or a system integrated into the tool. The device includes a stool collection module for collecting stool samples from a subject using the toilet; an extraction module for extracting one or more biomarkers from the collected stool samples; a testing module for testing the one or more biomarkers to identify the presence of target RNA, e.g., viruses, such as SARS-CoV-2, cancers, and the like; and a sanitization module for sanitizing the toilet between users.

Resumen de: WO2023092023A2

Disclosed are methods of preventing or treating COVID-19 caused by a coronavirus infection or variants thereof by administration to a subject in need thereof a synthetic MVA-based vaccine. Also disclosed are methods of preventing or treating a coronavirus infection, or increasing an immune response in a subject who has previously received a SARS-CoV-2 vaccine by administration to the subject or a booster dose of a synthetic MVA-based vaccine.

Resumen de: WO2023092126A1

Described are rapid, point of care tests to detect circulating neutralizing antibodies against SARS-CoV-2 in a biological sample obtained from patients.

Resumen de: WO2023091119A1

The invention relates to a method based on the electrochemical impedance spectroscopy method for the sensitive and selective determination of SARS-CoV-2 S1 protein for the diagnosis of COVID-19 disease, an impedimetric immunosensor, and a method for preparation thereof.

Resumen de: WO2023091118A1

The invention relates to an enzymatic-based method by using amperometry technique for sensitive and selective determination of the SARS-CoV-2 S1 protein for the diagnosis of COVID-19 disease, an immunosensor, and a method of preparation thereof.

Resumen de: WO2023091107A1

This invention relates to the formulation of active substances Molnupiravir and Montelukast together into tablet/capsule formulations and to the activity of these formulations against Covid-19.

Resumen de: WO2023090947A1

Disclosed is a polyethylene glycol-artemisinin compound-containing pharmaceutical composition for preventing or treating coronavirus infectious disease. The pharmaceutical composition has low toxicity and excellent antiviral activity against the SARS-CoV-2 virus that causes COVID-19, and can thus be advantageously used to prevent or treat coronavirus infectious disease without side effects.

Resumen de: WO2023089862A1

In one embodiment, provided is a Stephania cephalantha-derived alkaloid-containing preparation for treating SARS-CoV-2 infection. According to one embodiment of the present invention, the preparation for treating SARS-CoV-2 infection contains cepharanthine, isotetrandrine, cycleanine and berbamine. This preparation for treating SARS-CoV-2 infection is for treating infection caused by a SARS-CoV-2 variant. According to one embodiment of the present invention, provided is a Stephania cephalantha-derived alkaloid-containing preparation for treating SARS-CoV-2 infection.

Resumen de: WO2023089850A1

Provided by the present invention are: a biomarker for COVID-19 diagnosis comprising a transcription product of the human DOCK2 gene or a reverse transcription product of the transcription product; a screening method for drugs to treat or prevent COVID-19 from becoming severe that uses expression of DOCK2 as an index; a method for treating COVID-19 that administers a drug that enhances the expression or increases the activity of the human DOCK2 gene; and a method for preventing COVID-19 from becoming severe that administers a drug that enhances the expression or increases the activity of the human DOCK2 gene to a patient at high risk for COVID-19 becoming severe.

Resumen de: WO2023089371A1

The present invention discloses methods and means for the quick and early detection of the infection caused by the novel SARS-CoV-2 coronavirus (COVID-19 etiological agent) by means of interaction with specific DNA aptamers coupled to various markers and obtained by means of in vitro selection using recombinant proteins. According to the invention, the combination of signals produced by the aptamer-protein complexes in various platforms leads to an accurate and specific diagnosis of SARS-CoV-2 viraemia. The functionality and quality of the aptamers of the invention is demonstrated with fluorescence sandwich assays, and said aptamers can be adapted as aptasensors in various molecular diagnostics technologies.

Resumen de: WO2023088418A1

Provided are certain antiviral agents, pharmaceutical compositions thereof, and methods of use thereof.